Endo's Generic OxyContin To Launch Following Patent Invalidation

D.C. federal appeals court upholds a ruling invalidating Purdue's patents due to inequitable conduct by the brand company. Endo says it holds 180-day exclusivity on three of four doses of oxycodone extended-release. Purdue plans to seek en banc review of the appellate panel's decision.